IMVT

Immunovant, Inc. Common Stock

26.09

USD

IMVT Earnings Reports

Positive Surprise Ratio

IMVT beat 10 of 23 last estimates.

43%

Next Report

In 3 Days

Date of Next Report

Feb 06, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.72

Implied change from Q2 26 (Revenue/ EPS)

-1.37%

Implied change from Q3 25 (Revenue/ EPS)

-5.26%

Immunovant, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, IMVT reported earnings of -0.73 USD per share (EPS) for Q2 26, beating the estimate of -0.73 USD, resulting in a 0.21% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.09% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 17 analysts forecast an EPS of -0.72 USD, with revenue projected to reach -- USD, implying an decrease of -1.37% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Twist Bioscience Corporation Common Stock

Report Date

Feb 02, 2026 For Q1 26

Estimate

-$0.43

Actual

-$0.50

Surprise

-14.00%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were Immunovant, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Immunovant, Inc. Common Stock reported EPS of -$0.73, missing estimates by 0.21%, and revenue of $0.00, 0% as expectations.

How did the market react to Immunovant, Inc. Common Stock's Q2 2026 earnings?

The stock price moved up 0.09%, changed from $23.35 before the earnings release to $23.37 the day after.

When is Immunovant, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 06, 2026.

What are the forecasts for Immunovant, Inc. Common Stock's next earnings report?

Based on 17 analysts, Immunovant, Inc. Common Stock is expected to report EPS of -$0.72 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.